TPST TEMPEST THERAPEUTICS INC

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET

BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global randomized Phase 1b/2 combination study of amezalpat (TPST-1120) with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m. ET.

To join the conference call via phone and participate in the live Q&A session, please pre-register online to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the investor section of the Tempest website at . The webcast will be available for replay for 30 days.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at .

Investor & Media Contacts

Sylvia Wheeler

Wheelhouse Life Science Advisors



Aljanae Reynolds

Wheelhouse Life Science Advisors



 
i If approved by the FDA


EN
18/06/2024

Underlying

TPSTTEMPEST THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEMPEST THERAPEUTICS INC

 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targ...

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assetsDevelopment approach prioritizes partner-funded and externally supported programs to generate clinical data before deploying significant internal capitalPipeline expansion includes TPST-4003, an in vivo dual-targeting CD19/BCMA CAR-T, with potential near-term milestones BRISBANE, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TP...

February 11, 2026 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting C...

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027Operational runway extended to mid-2027, supporting multiple potential value-generating milestonesMatt Angel, Ph.D., joins Tempest as President and CEOPreviously announced transaction closed following stockholder approval of share issuance at the 2025 Annual Meeting on January 27, 2026 BRISBANE,...

February 4, 2026 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Announces Record Date for Anticipated Dividend Distribution of...

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the “Record Date”) for the distribution of warrants to purchase Tempest common stock (“Warrants”) as a dividend (the “Warrant Dividends”), as contemplated by Tempest’s previously announced Asset Purchase Agreement (the “As...

January 20, 2026 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Announces Closing of Up To $8.35 Million Registered Direct Off...

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules $4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced the closing ...

November 26, 2025 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Announces Up To $8.35 Million Registered Direct Offering of Co...

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules $4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants BRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered int...

November 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch